Fracture Prevention in Osteoporosis
The University of Cincinnati College of Medicine designates this educational activity for a maximum of two (2) AMA PRA Category 1 CME Creditsâ„¢. Physicians should only claim credit commensurate with the extent of their participation in this activity.
The University of Cincinnati College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor medical education for physicians.
The GMR Group-Health Insights is an approved provider of continuing nursing education by the Pennsylvania State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation and is a provider approved by the California Board of Registered Nursing, California Provider # CEP 12643.
The GMR Group-Health Insights is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program offers a total of 1.75 contact hours or 0.175 CEUs. ACPE # 404-000-06-001-H01.
After reading "Fracture Prevention in Osteoporosis" please complete the program evaluation and fill out the answer key for each of the following questions.
1. According to the National Osteoporosis Foundation, how many individuals in the United States have, or are at risk for, osteoporosis?
2. Osteoporosis has been estimated to result in how many fragility fractures yearly?
3. The majority of osteoporosis-related fractures are _____.
4. Absent osteoporosis, bone turnover _____.
5. By 2020, yearly healthcare spending for osteoporotic-related fracture in the United States is expected to reach _____.
6. Risk factors for osteoporosis-related fracture include which of the following?
7. Which of the following is a possible physical sign of vertebral fracture?
8. Which of the following is a biochemical marker of bone formation?
9. The World Health Organization defines the threshold for a diagnosis of osteoporosis as a T-score of less than _____.
10. Medicare covers bone mineral density (BMD) testing every 2 years for which of the following groups?
11. In the National Osteoporosis Risk Assessment study, the presence of osteopenia increased the risk for fracture by _____.
12. In the Study of Osteoporotic Fracture trial, the risk for hip fracture in women over the age of 65 years increased _____.
13. The National Osteoporosis Foundation advocates starting pharmacotherapy to reduce fracture risk in which groups of women?
14. Alendronate has been shown to reduce the risk for vertebral and nonvertebral fracture _____.
15. After starting therapy, risedronate reduces the risk for vertebral and nonvertebral fracture within _____.
16. In reducing the risk for nonvertebral fracture, calcitonin has been shown to be less effective than either _____.
17. A study using "real-world" data from the Protocare Sciences Integrated Medical and Pharmaceutical Claims Database demonstrated that, compared with calcitonin or alendronate treatment, risedronate reduced the adjusted risk for nonvertebral fracture at 6 months by _____.
18. The results of an observational study using data from the Protocare Sciences Database indicated that the annual nonvertebral fracture-related medical cost in patients treated with risedronate is _____.
19. In the study by Miller, using data from the Protocare Sciences Database, the risk for gastrointestinal (GI) side effects in patients with a history of GI events was _____.
20. In the observational cost analysis study by Kane, the annual direct medical costs for GI events in patients treated with risedronate were _____.
To enhance understanding of current practices in fracture prevention.
Managed care pharmacy directors, medical directors, and other managed care executives . . .
Upon completion of this activity, participants will be able to:
There is no fee for this program.
Expiration date: 05-31-07
This publication was made possible by funding from The Alliance for Better Bone Health, P&G/Sanofi-Aventis.
The contents of this supplement may include information regarding the use of products that may be inconsistent outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.